Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFKB1 | P19838 | 5/20 | 0.43 |
| ▸ | JUN | P05412 | 3/20 | 0.43 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.43 |
| ▸ | RELA | Q04206 | 3/20 | 0.43 |
| ▸ | CA12 | O43570 | 5/20 | 0.39 |
| ▸ | CA1 | P00915 | 5/20 | 0.39 |
| ▸ | CA2 | P00918 | 5/20 | 0.39 |
| ▸ | CA7 | P43166 | 5/20 | 0.39 |
| ▸ | CA9 | Q16790 | 5/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | ATF1 | P18846 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29827391 | 1.00 | NFKB1 (0.43) | NFKB1JUNNFKB2RELACA12 | |
| SCHEMBL27199300 | 0.84 | L3MBTL1 (0.41) | NFKB1JUNNFKB2RELAKDM4E | |
| SCHEMBL21443520 | 0.81 | MEN1 (0.44) | ALDH1A1POLBMAPTNPC1MEN1 | |
| SCHEMBL25014139 | 0.81 | ALDH1A1 (0.40) | NFKB1JUNNFKB2RELACA12 | |
| SCHEMBL30110408 | 0.81 | NFKB1 (0.46) | NFKB1JUNNFKB2RELAKDM4E | |
| SCHEMBL1602748 | 0.81 | NFKB1 (0.46) | NFKB1JUNNFKB2RELAKDM4E | |
| SCHEMBL1320432 | 0.78 | NFKB1 (0.49) | NFKB1JUNNFKB2RELAATF1 | |
| SCHEMBL19282905 | 0.77 | NFKB1 (0.43) | NFKB1JUNNFKB2RELAKDM4E | |
| SCHEMBL476310 | 0.77 | ALDH1A1 (0.59) | NFKB1KDM4EALDH1A1ATF1MAPT | |
| SCHEMBL6643357 | 0.77 | NFKB1 (0.49) | NFKB1JUNNFKB2RELAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4444293-A2 | METHODS OF PREPARING SUBSTITUTED PYRAZOLOPYRIMIDINES | KSQ Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | claimed |
| CN-118369094-A | Process for preparing substituted pyrazolopyrimidines | KSQ治疗公司 | 2024-07-19 | — | — | CN | claimed |
| WO-2023108048-A2 | METHODS OF PREPARING SUBSTITUTED PYRAZOLOPYRIMIDINES | KSQ Therapeutics, Inc. (US) | 2023-06-15 | — | — | WO | claimed |
| US-20210309640-A1 | PHARMACEUTICAL SALTS OF PYRIMIDINE DERIVATIVES AND METHOD OF TREATING DISORDERS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-10-07 | — | — | US | claimed |
| EP-3793993-A1 | PHARMACEUTICAL SALTS OF PYRIMIDINE DERIVATIVES AND METHOD OF TREATING DISORDERS | ARIAD Pharmaceuticals, Inc. (US) | 2021-03-24 | — | — | EP | claimed |
| CN-112313223-A | Pharmaceutically acceptable salts of pyrimidine derivatives and methods of treating conditions | 阿瑞雅德制药公司 | 2021-02-02 | — | — | CN | claimed |
| CN-119219605-A | Bifunctional compound for targeted degradation of EGFR protein, and pharmaceutical composition, pharmaceutical preparation and application thereof | 北京福元医药股份有限公司 | 2024-12-31 | — | — | CN | disclosed |
| CN-119019383-A | Compounds used as kinase inhibitors and application thereof | 郑州同源康医药有限公司 | 2024-11-26 | — | — | CN | disclosed |
| EP-4444293-A2 | METHODS OF PREPARING SUBSTITUTED PYRAZOLOPYRIMIDINES | KSQ Therapeutics, Inc. (US) | 2024-10-16 | — | — | EP | disclosed |
| US-20240327402-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PHARMACY | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2024-10-03 | — | — | US | disclosed |
| US-12084431-B2 | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-09-10 | — | — | US | disclosed |
| CN-115175902-B | Compounds used as kinase inhibitors and application thereof | 郑州同源康医药有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-118369094-A | Process for preparing substituted pyrazolopyrimidines | KSQ治疗公司 | 2024-07-19 | — | — | CN | disclosed |
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
| US-7504410-B2 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AKTIENGESELLSCHAFT (DE) | 2009-03-17 | — | — | US | disclosed |
| CN-1717396-A | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2006-01-04 | — | — | CN | disclosed |
| EP-1565446-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-08-24 | — | — | EP | disclosed |
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2004-09-23 | — | — | US | disclosed |
| WO-2004048343-A1 | CHK-, PDK- AND AKT-INHIBITORY PYRIMIDINES, THEIR PRODUCTION AND USE AS PHARMACEUTICAL AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12084431-B2 | Pharmaceutical salts of pyrimidine derivatives and method of treating disorders | DPYD, TYMP, TYMS | NFKB1 3225/4885JUN 1983/4885NFKB2 3521/4885 |
| US-20210309640-A1 | PHARMACEUTICAL SALTS OF PYRIMIDINE DERIVATIVES AND METHOD OF TREATING DISORDERS | DPYD, TYMP, TYMS | NFKB1 3351/4885JUN 1993/4885NFKB2 3655/4885 |
| US-20040186118-A1 | Chk-, Pdk- and Akt-inhibitory pyrimidines, their production and use as pharmaceutical agents | DCK, PDPK1, DTYMK | NFKB1 1127/4885JUN 770/4885NFKB2 918/4885 |
| US-20240327402-A1 | PYRIMIDINE OR PYRIDINE DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PHARMACY | WEE1, WEE2, EGFR | NFKB1 2913/4885JUN 1237/4885NFKB2 3614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.